Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Goff BA, Mandel LS, Drescher CW, Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109:221-7
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-66
   PubMed Web of Science ®Google Scholar
• Colombo N, Van Gorp T, Parma G, Ovarian cancer. Crit Rev Oncol Hematol 2006;60:159-79
   PubMed Web of Science ®Google Scholar
• Gultekin M, Diribas K, Buru E, Interval debulking in epithelial ovarian carcinomas: the past, present and the future. Eur J Gynaecol Oncol 2008;29:242-5
   PubMedGoogle Scholar
• Sugiyama T, Kamura T, Kigawa J, Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9
   PubMed Web of Science ®Google Scholar
• Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971;37:1-9
   PubMedGoogle Scholar
• Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-9
   PubMedGoogle Scholar
• Itamochi HK, J. Incidence of ovarian cancer in Japan. Obstet Gynecol (Tokyo) 2005;5:545-9
   Google Scholar
• Schiller W. Mesonephroma ovarii. Am J Cancer 1939;35:1-21
   Google Scholar
• Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumours. (International Histological Classification No.9). World Health Organization 1973. p. 17-54
   Google Scholar
• Yoonessi M, Weldon D, Satchidand SK, Crickard K. Clear cell ovarian adenocarcinoma. J Surg Oncol 1984;27:289-97
   PubMedGoogle Scholar
• Itamochi H, Kigawa J, Sultana H, Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002;93:723-8
   PubMedGoogle Scholar
• Behbakht K, Randall TC, Benjamin I, Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70:255-8
   PubMed Web of Science ®Google Scholar
• Mandai M, Yamaguchi K, Matsumura N, Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 2009;14:383-91
   PubMed Web of Science ®Google Scholar
• Kobayashi H. Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol 2009;14:378-82
   PubMed Web of Science ®Google Scholar
• Stern RC, Dash R, Bentley RC, Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 2001;20:133-9
   PubMed Web of Science ®Google Scholar
• Modesitt SC, Tortolero-Luna G, Robinson JB, Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 2002;100:788-95
   PubMed Web of Science ®Google Scholar
• Jenison EL, Montag AG, Griffiths CT, Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71
   PubMed Web of Science ®Google Scholar
• Ogawa S, Kaku T, Amada S, Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 2000;77:298-304
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Mandai M, Toyokuni S, Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008;14:32-40
   PubMed Web of Science ®Google Scholar
• Enomoto T, Kuragaki C, Yamasaki M, Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 2003;22(A1797):447
   Google Scholar
• Ho CM, Huang YJ, Chen TC, Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004;94:197-203
   PubMedGoogle Scholar
• Goff BA, Sainz de la Cuesta R, Muntz HG, Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-17
   PubMed Web of Science ®Google Scholar
• Mizuno M, Kikkawa F, Shibata K, Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006;94:138-43
   PubMedGoogle Scholar
• Winter WE III, Maxwell GL, Tian C, Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-7
   PubMed Web of Science ®Google Scholar
• Winter WE III, Maxwell GL, Tian C, Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008;26:83-9
   PubMed Web of Science ®Google Scholar
• Chan JK, Teoh D, Hu JM, Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-6
   Google Scholar
• Pectasides D, Fountzilas G, Aravantinos G, Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006;102:285-91
   PubMedGoogle Scholar
• Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008;99:653-8
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nikaido T, Toki T, Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999;85:669-77
   PubMedGoogle Scholar
• Oishi T, Itamochi H, Kigawa J, Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2007;17:1040-6
   PubMedGoogle Scholar
• Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999;59:4148-54
   PubMed Web of Science ®Google Scholar
• Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genistein-induced G2/M arrest and inhibits apoptosis. Carcinogenesis 2000;21:1941-5
   PubMedGoogle Scholar
• Inohara H, Raz A. Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 1995;55:3267-71
   PubMed Web of Science ®Google Scholar
• Matarrese P, Fusco O, Tinari N, Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000;85:545-54
   PubMed Web of Science ®Google Scholar
• Inohara H, Akahani S, Raz A. Galectin-3 stimulates cell proliferation. Exp Cell Res 1998;245:294-302
   PubMed Web of Science ®Google Scholar
• Yang RY, Liu FT. Galectins in cell growth and apoptosis. Cell Mol Life Sci 2003;60:267-76
   PubMed Web of Science ®Google Scholar
• Yoshida S, Furukawa N, Haruta S, Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev 2009;35:608-15
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Sakamoto M, Yasuda J, Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163:2503-12
   PubMed Web of Science ®Google Scholar
• Marquez RT, Baggerly KA, Patterson AP, Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005;11:6116-26
   PubMedGoogle Scholar
• Zorn KK, Bonome T, Gangi L, Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-30
   PubMed Web of Science ®Google Scholar
• Kim A, Enomoto T, Serada S, Enhanced expression of annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer 2009;125:2316-22
   PubMed Web of Science ®Google Scholar
• Morita A, Miyagi E, Yasumitsu H, Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 2006;6:5880-90
   PubMed Web of Science ®Google Scholar
• Miao Y, Cai B, Liu L, Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2009;19:1545-9
   PubMedGoogle Scholar
• Kobayashi H, Yamada Y, Kanayama S, The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 2009;19:471-79
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Mandai M, Oura T, Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010;29:1741-52
   PubMedGoogle Scholar
• Kaetzel MA, Hazarika P, Dedman JR. Differential tissue expression of three 35-kDa annexin calcium-dependent phospholipid-binding proteins. J Biol Chem 1989;264:14463-70
   PubMed Web of Science ®Google Scholar
• Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002;82:331-71
   PubMed Web of Science ®Google Scholar
• Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008;216:131-40
   PubMed Web of Science ®Google Scholar
• Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005;6:449-61
   PubMed Web of Science ®Google Scholar
• Rescher U, Gerke V. Annexins – unique membrane binding proteins with diverse functions. J Cell Sci 2004;117:2631-9
   PubMed Web of Science ®Google Scholar
• Liemann S, Huber R. Three-dimensional structure of annexins. Cell Mol Life Sci 1997;53:516-21
   PubMed Web of Science ®Google Scholar
• Rand JH. The annexinopathies: a new category of diseases. Biochim Biophys Acta 2000;1498:169-73
   PubMedGoogle Scholar
• Hayes MJ, Moss SE. Annexins and disease. Biochem Biophys Res Commun 2004;322:1166-70
   PubMed Web of Science ®Google Scholar
• Alfonso P, Canamero M, Fernandez-Carbonie F, Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res 2008;7:4247-55
   PubMed Web of Science ®Google Scholar
• Duncan R, Carpenter B, Main LC, Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 2008;98:426-33
   PubMed Web of Science ®Google Scholar
• Edwards HC, Crumpton MJ. Ca2+-dependent phospholipid and arachidonic acid binding by the placental annexins VI and IV. Eur J Biochem 1991;198:121-9
   PubMedGoogle Scholar
• Zanotti G, Malpeli G, Gliubich F, Structure of the trigonal crystal form of bovine annexin IV. Biochem J 1998;329(Pt 1):101-6
   PubMedGoogle Scholar
• Newman RH, Leonard K, Crumpton MJ. 2D crystal forms of annexin IV on lipid monolayers. FEBS Lett 1991;279:21-4
   PubMedGoogle Scholar
• Kaetzel MA, Mo YD, Mealy TR, Phosphorylation mutants elucidate the mechanism of annexin IV-mediated membrane aggregation. Biochemistry 2001;40:4192-9
   PubMed Web of Science ®Google Scholar
• Oling F, Santos JS, Govorukhina N, Structure of membrane-bound annexin A5 trimers: a hybrid cryo-EM – X-ray crystallography study. J Mol Biol 2000;304:561-73
   PubMed Web of Science ®Google Scholar
• Pigault C, Follenius-Wund A, Schmutz M, Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol 1994;236:199-208
   PubMedGoogle Scholar
• Voges D, Berendes R, Burger A, Three-dimensional structure of membrane-bound annexin V. A correlative electron microscopy-X-ray crystallography study. J Mol Biol 1994;238:199-213
   Google Scholar
• Reviakine II, Bergsma-Schutter W, Brisson A. Growth of protein 2-D crystals on supported planar lipid bilayers imaged in situ by AFM. J Struct Biol 1998;121:356-61
   PubMedGoogle Scholar
• Kaetzel MA, Chan HC, Dubinsky WP, A role for annexin IV in epithelial cell function. Inhibition of calcium-activated chloride conductance. J Biol Chem 1994;269:5297-302
   PubMed Web of Science ®Google Scholar
• Chan HC, Kaetzel MA, Gotter AL, Annexin IV inhibits calmodulin–dependent protein kinase II-activated chloride conductance. A novel mechanism for ion channel regulation. J Biol Chem 1994;269:32464-8
   PubMed Web of Science ®Google Scholar
• Xie W, Kaetzel MA, Bruzik KS, Inositol 3,4,5,6-tetrakisphosphate inhibits the calmodulin-dependent protein kinase II-activated chloride conductance in T84 colonic epithelial cells. J Biol Chem 1996;271:14092-7
   PubMed Web of Science ®Google Scholar
• Sohma H, Ohkawa H, Hashimoto E, Alteration of annexin IV expression in alcoholics. Alcohol Clin Exp Res 2001;25:55S-58S
   PubMedGoogle Scholar
• Ohkawa H, Sohma H, Sakai R, Ethanol-induced augmentation of annexin IV in cultured cells and the enhancement of cytotoxicity by overexpression of annexin IV by ethanol. Biochim Biophys Acta 2002;1588:217-25
   PubMed Web of Science ®Google Scholar
• Zimmermann U, Balabanov S, Giebel J, Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett 2004;209:111-18
   PubMed Web of Science ®Google Scholar
• Sitek B, Luttges J, Marcus K, Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 2005;5:2665-79
   PubMed Web of Science ®Google Scholar
• Xin W, Rhodes DR, Ingold C, Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol 2003;162:255-61
   PubMed Web of Science ®Google Scholar
• Han EK, Tahir SK, Cherian SP, Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 2000;83:83-8
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6
   PubMed Web of Science ®Google Scholar
• Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009;8:33-40
   PubMed Web of Science ®Google Scholar
• Sohma H, Ohkawa H, Sakai R, Augmentation of ethanol-induced cell damage and activation of nuclear factor-kappaB by annexin IV in cultured cells. Alcohol Clin Exp Res 2003;27:64S-67S
   Google Scholar
• Jeon YJ, Kim DH, Jung H, Annexin A4 interacts with the NF-kappaB p50 subunit and modulates NF-kappaB transcriptional activity in a Ca2+-dependent manner. Cell Mol Life Sci 2010;67:2271-81
   PubMed Web of Science ®Google Scholar
• Draeger A, Wray S, Babiychuk EB. Domain architecture of the smooth-muscle plasma membrane: regulation by annexins. Biochem J 2005;387:309-14
   PubMedGoogle Scholar
• Monastyrskaya K, Babiychuk EB, Draeger A. The annexins: spatial and temporal coordination of signaling events during cellular stress. Cell Mol Life Sci 2009;66:2623-42
   PubMed Web of Science ®Google Scholar
• Kidd JF, Pilkington MF, Schell MJ, Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem 2002;277:6504-10
   PubMed Web of Science ®Google Scholar
• Yan X, Yin J, Yao H, Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res 2010;70:1616-24
   PubMedGoogle Scholar
• Scully RE. Recent progress in ovarian cancer. Hum Pathol 1970;1:73-98
   PubMedGoogle Scholar